ReviewJournal of clinical medicine2022
Risk Stratification in Patients with Acute Pulmonary Embolism: Current Evidence and Perspectives.
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06756373 (Adherence to International Guidelines Directed Risk Stratification and Management of Acute Pulmonary Embolism, an Egyptian Experience), which is not on this map. Cited by 36 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Adherence to International Guidelines Directed Risk Stratification and Management of Acute Pulmonary Embolism, an Egyptian Experience
Who cites it
36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Pooled it
- Chinese expert consensus on prevention, diagnosis, and management of venous thromboembolism in adult burn patients (2024).Military Medical Research · 2025Guideline
- Brazilian guidelines for the pharmacological treatment of pulmonary embolism. Official document of the Brazilian Thoracic Association based on the GRADE methodology.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2025Guideline
- Prediction of 30-Day Complicated Clinical Course in Acute Pulmonary Embolism: A Prospective Cohort Comparison of the ESC, Bova, and Modified FAST Models.Diagnostics (Basel, Switzerland) · 2026Article
- Association of Composite Metabolic, Inflammatory, and Nutritional Indices with Right Ventricular Dysfunction in Acute Pulmonary Embolism: A Retrospective Cohort Study.Journal of cardiovascular development and disease · 2026Article
- Standardizing leave of absence and round-trip protocols for surgical management of pulmonary embolism.Journal of vascular surgery. Venous and lymphatic disorders · 2026Article
- Admission Endothelial Activation and Stress Index and Echocardiographic RV-PA Coupling for Early Risk Stratification in Intermediate-Risk Acute Pulmonary Embolism.Journal of clinical medicine · 2026Article
- Polycythemia Vera, Thrombophilia, CTEPH, Cerebral Venous Sinus Thrombosis and Vertebral Artery Occlusion: A Case-Illustrated Narrative Review of Competing Thrombotic and Hemorrhagic Risks.Life (Basel, Switzerland) · 2026Article
- Short-term outcomes of ultrasound-assisted catheter-directed thrombolysis and mechanical thrombectomy in management of intermediate-risk pulmonary embolism.Journal of vascular surgery. Venous and lymphatic disorders · 2026Article
- Trends and Therapeutic Imperatives in Pulmonary Embolism Therapy.Journal of the Society for Cardiovascular Angiography & Interventions · 2026Article
- Outcomes of EKOS (Ultrasound-Assisted Thrombolysis) for Intermediate-High-Risk Pulmonary Embolism: A PERT-Guided Cohort Study.Interdisciplinary cardiovascular and thoracic surgery · 2026Article
- Risk Stratification in Pulmonary Embolism: The Expanding Role of Biomarkers.Biomedicines · 2026Review
- Prognostic Value of Arterial Lactate in Predicting In-Hospital Mortality in Acute Pulmonary Embolism.Diagnostics (Basel, Switzerland) · 2026Article
- Thrombolytic Therapy in High-Risk Pulmonary Embolism with Thrombocytopenia: Case Report and Literature Review.Journal of clinical medicine · 2026Article
- Clinical Profile and Admission Outcomes of Patients With Acute Pulmonary Embolism at a Resource-Constrained Hospital in Ghana: A Retrospective Pilot Study.Health science reports · 2026Article
- Contemporary Challenges in Venous Thromboembolism: Evolving Populations and Implications for Management and Risk Stratification.Journal of clinical medicine · 2026Review
- ABO Blood Group and Biomarker-Based Risk in Acute Pulmonary Embolism: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- A study on the relationship between mMRC dyspnea scale and both risk stratification and poor prognosis in patients with acute pulmonary embolism.Frontiers in cardiovascular medicine · 2026Article
- Evaluation of microbial-derived metabolites in patients with acute pulmonary embolism: findings from the MICTEP study.ERJ open research · 2025Article
- Role of catheter-based interventions in treating pulmonary embolism.World journal of cardiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Risk stratification is one of the cornerstones of the management of acute pulmonary embolism (PE) and determines the choice of both diagnostic and therapeutic strategies. The first step is the identification of patent circulatory failure, as it is associated with a high risk of immediate mortality and requires a rapid diagnosis and prompt reperfusion. The second step is the estimation of 30-day mortality based on clinical parameters (e.g., original and simplified version of the pulmonary embolism severity index): low-risk patients without right ventricular dysfunction are safely managed with ambulatory anticoagulation. The remaining group of hemodynamically stable patients, labeled intermediate-risk PE, requires hospital admission, even if most of them will heal without complications. In recent decades, efforts have been made to identify a subgroup of patients at an increased risk of adverse outcomes (intermediate-high-risk PE), who might benefit from a more aggressive approach, including reperfusion therapies and admission to a monitored unit. The cur-rent approach, combining markers of right ventricular dysfunction and myocardial injury, has an insufficient positive predictive value to guide primary thrombolysis. Sensitive markers of circulatory failure, such as plasma lactate, have shown interesting prognostic accuracy and may play a central role in the future. Furthermore, the improved security of reduced-dose thrombolysis may enlarge the indication of this treatment to selected intermediate-high-risk PE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.